Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5921_Библиотеки_им_академика_М_И_Перельмана
.pdf
36.
Rennard SI, Basset G, Lecossier D, O’Donnell KM, Pinkston P, Martin PG, et al.
Estimation of volume of epithelial lining luid recovered by lavage using urea as
marker of dilution. J Appl Physiol (1985). 1986;60(2):532–8.
[PubMed]
37.
Brandsma J, Goss VM, Yang X, Bakke PS, Caruso M, Chanez P, et al. Lipid
phenotyping of lung epithelial lining luid in healthy human volunteers.
Metabolomics. 2018;14(10):123.
[PubMed][PubMedCentral]
38.
Suresh K, Shimoda LA. Lung circulation. Compr Physiol. 2016;6(2):897–943.
[PubMed][PubMedCentral]
39.
Jain V, Bordes SJ, Bhardwaj A. Physiology, pulmonary circulatory system. In:
StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2022.
40.
Scherließ R, Bock S, Bungert N, Neustock A, Valentin L. Particle engineering in
dry powders for inhalation. Eur J Pharm Sci. 2022;172:106158.
[PubMed]
41.
Hickey AJ. Emerging trends in inhaled drug delivery. Adv Drug Deliv Rev.
2020;157:63–70.
[PubMed][PubMedCentral]
42.
Lin YW, Wong J, Qu L, Chan HK, Zhou QT. Powder production and particle
engineering for dry powder inhaler formulations. Curr Pharm Des.
2015;21(27):3902–16.
[PubMed]
43.
Hickey AJ. Pharmaceutical inhalation aerosol technology. Boca Raton: CRC
Press; 2003.
44.
Hartung N, Borghardt JM. A mechanistic framework for a priori pharmacokinetic
predictions of orally inhaled drugs. PLoS Comput Biol. 2020;16(12):e1008466.
[PubMed][PubMedCentral]
45.
Hochhaus G, Horhota S, Hendeles L, Suarez S, Rebello J. Pharmacokinetics of
orally inhaled drug products. AAPS J. 2015;17(3):769–75.
[PubMed][PubMedCentral]
46.
Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for
pulmonary drug delivery. Pharm Res. 2007;24(3):411–37.
[PubMed]
https://t.me/medicina_free
47.
Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive
review. Pharmaceutics. 2020;13(1):31.
[PubMed][PubMedCentral]
48.
Eedara BB, Bastola R, Das SC. Dissolution and absorption of inhaled drug
particles in the lungs. Pharmaceutics. 2022;14(12):2667.
[PubMed][PubMedCentral]
49.
Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med.
2010;363(23):2233–47.
[PubMed][PubMedCentral]
50.
Shin GH, Kim JT. Comparative study of chitosan and oligochitosan coatings on
mucoadhesion of curcumin nanosuspensions. Pharmaceutics. 2021;13(12):2154.
[PubMed][PubMedCentral]
51.
Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery.
Front Pharmacol. 2021;12:618411.
[PubMed][PubMedCentral]
52.
Olsson B, Bondesson E, Borgstro m L, Edsba cker S, Eirefelt S, Ekelund K, et al.
Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey
AJ, editors. Controlled pulmonary drug delivery. New York: Springer; 2011. p.
21–50.
53.
Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug
delivery. Proc Am Thorac Soc. 2004;1(4):338–44.
[PubMed]
54.
Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs.
Molecules. 2009;14(9):3754–79.
[PubMed][PubMedCentral]
55.
Groneberg DA, Fischer A, Chung KF, Daniel H. Molecular mechanisms of
pulmonary peptidomimetic drug and peptide transport. Am J Respir Cell Mol
Biol. 2004;30(3):251–60.
[PubMed]
56.
Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets:
emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–60.
[PubMed][PubMedCentral]
57.
Nigam SK. What do drug transporters really do? Nat Rev Drug Discov.
2015;14(1):29–44.
https://t.me/medicina_free
[PubMed]
58.
John TA, Vogel SM, Minshall RD, Ridge K, Tiruppathi C, Malik AB. Evidence for
the role of alveolar epithelial gp60 in active transalveolar albumin transport in
the rat lung. J Physiol. 2001;533(Pt 2):547–59.
[PubMed][PubMedCentral]
59.
Lockett AD, Brown MB, Santos-Falcon N, Rush NI, Oueini H, Oberle AJ, et al.
Active traficking of alpha 1 antitrypsin across the lung endothelium. PLoS One.
2014;9(4):e93979.
[PubMed][PubMedCentral]
60.
Kim KJ, Malik AB. Protein transport across the lung epithelial barrier. Am J
Physiol Lung Cell Mol Physiol. 2003;284(2):L247–59.
[PubMed]
61.
Boer F. Drug handling by the lungs. Br J Anaesth. 2003;91(1):50–60.
[PubMed]
62.
Roerig DL, Kotrly KJ, Dawson CA, Ahlf SB, Gualtieri JF, Kampine JP. First-pass
uptake of verapamil, diazepam, and thiopental in the human lung. Anesth Analg.
1989;69:461–6.
[PubMed]
63.
Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated
hepatocytes: mechanisms and consequences for quantitative clearance
prediction. Drug Metab Dispos. 2007;35(8):1325–32.
[PubMed]
64.
Frutiger A, Tanno A, Hwu S, Tiefenauer RF, Vo ros J, Nakatsuka N. Nonspeciic
binding—fundamental concepts and consequences for biosensing applications.
Chem Rev. 2021;121(13):8095–160.
[PubMed]
65.
Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in
xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory
and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43:149–73.
[PubMed]
66.
Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung.
Curr Drug Metab. 2006;7(8):939–48.
[PubMed]
https://t.me/medicina_free
67.
Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, et al. A comparison
of the expression and metabolizing activities of phase I and II enzymes in freshly
isolated human lung parenchymal cells and cryopreserved human hepatocytes.
Drug Metab Dispos. 2007;35(10):1797–805.
[PubMed]
68.
Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein
drug delivery. Ther Deliv. 2013;4(11):1443–67.
[PubMed]
69.
Guo Y, Bera H, Shi C, Zhang L, Cun D, Yang M. Pharmaceutical strategies to extend
pulmonary exposure of inhaled medicines. Acta Pharm Sin B. 2021;11(8):2565–
84.
[PubMed][PubMedCentral]
70.
Lombry C, Edwards DA, Preat V, Vanbever R. Alveolar macrophages are a
primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung
Cell Mol Physiol. 2004;286(5):L1002–8.
[PubMed]
71.
Pauluhn J, Mohr U. Inhalation studies in laboratory animals--current concepts
and alternatives. Toxicol Pathol. 2000;28(5):734–53.
[PubMed]
72.
Wylie JL, House A, Mauser PJ, Sellers S, Terebetski J, Wang Z, et al. Inhaled
formulation and device selection: bridging the gap between preclinical species
and irst-in-human studies. Ther Deliv. 2018;9(5):387–404.
[PubMed]
73.
Wong BA. Inhalation exposure systems: design, methods and operation. Toxicol
Pathol. 2007;35(1):3–14.
[PubMed]
74.
Guillon A, Montharu J, Vecellio L, Schubnel V, Roseau G, Guillemain J, et al.
Pulmonary delivery of dry powders to rats: tolerability limits of an intratracheal administration model. Int J Pharm. 2012;434(1–2):481–7.
[PubMed]
75.
Phalen RF, Mannix RC, Drew RT. Inhalation exposure methodology. Environ
Health Perspect. 1984;56:23–34.
[PubMed][PubMedCentral]
https://t.me/medicina_free
76.
Hoppentocht M, Hoste C, Hagedoorn P, Frijlink H, de Boer A. In vitro evaluation
of the DP-4M PennCentury (TM) insuflator. Eur J Pharm Biopharm.
2014;88:153–9.
[PubMed]
77.
Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Review: role of model-informed
drug development approaches in the lifecycle of drug development and
regulatory decision-making. Pharm Res. 2022;39(8):1669–80.
[PubMed][PubMedCentral]
78.
Lesko LJ. Perspective on model-informed drug development. CPT
Pharmacometrics Syst Pharmacol. 2021;10(10):1127–9.
[PubMed][PubMedCentral]
79.
Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, et al. Modelinformed drug discovery and development: current industry good practice and
regulatory expectations and future perspectives. CPT Pharmacometrics Syst
Pharmacol. 2019;8(2):87–96.
[PubMed][PubMedCentral]
80.
Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, DellaPasqua O, et al.
Good practices in model-informed drug discovery and development: practice,
application, and documentation. CPT Pharmacometrics Syst Pharmacol.
2016;5(3):93–122.
[PubMed][PubMedCentral]
81.
Mitra A, Wang Y. Applications of model informed drug development (MIDD) in
drug development lifecycle and regulatory review. Pharm Res. 2022;39(8):1663–
7.
[PubMed]
82.
Rostami AA, Campbell JL, Pithawalla YB, Pourhashem H, Muhammad-Kah RS,
Sarkar MA, et al. A comprehensive physiologically based pharmacokinetic
(PBPK) model for nicotine in humans from using nicotine-containing products
with different routes of exposure. Sci Rep. 2022;12(1):1091.
[PubMed][PubMedCentral]
83.
Himstedt A, Ba ckman P, Borghardt J. Physiologically-based pharmacokinetic
modeling after drug inhalation. In: Inhaled medicines optimizing development
through integration of in silico. London: Academic Press; 2021. p. 319–58.
84.
Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug
Deliv. 2012;25(3):140–7.
https://t.me/medicina_free
[PubMed][PubMedCentral]
85.
Zou H, Banerjee P, Leung SSY, Yan X. Application of pharmacokineticpharmacodynamic modeling in drug delivery: development and challenges.
Front Pharmacol. 2020;11:997.
[PubMed][PubMedCentral]
86.
Weibelzahl S, Weber G. Advantages, opportunities, and limits of empirical
evaluations: evaluating adaptive systems. Kunstl Intell. 2002;3:17–20.
87.
Himstedt A, Borghardt JM, Wicha SG. Inferring pulmonary exposure based on
clinical PK data: accuracy and precision of model-based deconvolution methods.
J Pharmacokinet Pharmacodyn. 2022;49(2):135–49.
[PubMed]
88.
Kandala B, Hochhaus G. Pharmacometrics in pulmonary diseases. In: Schmidt S,
Derendorf H, editors. Applied pharmacometrics. 1st ed. New York: Springer;
2014. p. 349–82.
89.
Zhuang X, Lu C. PBPK modeling and simulation in drug research and
development. Acta Pharm Sin B. 2016;6(5):430–40.
[PubMed][PubMedCentral]
90.
Shi C, Ignjatovic J, Liu T, Han M, Cun D, Đuris J, et al. In vitro – in vivo – in silico
approach in the development of inhaled drug products: nanocrystal-based
formulations with budesonide as a model drug. Asian J Pharm Sci.
2021;16(3):350–62.
[PubMed][PubMedCentral]
91.
Collingwood SP, Coe D, Pryde D, Lock R. Respiratory drug discovery, current
developments and future challenges: highlights from the Society of Medicines
Research Symposium, held on June 14 th, 2012–Horsham, UK. Drugs Future.
2012;37(8):619–25.
92.
Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the “bottom up”and
“top down” approaches in pharmacokinetic modelling: itting PBPK models to
observed clinical data. Br J Clin Pharmacol. 2015;79(1):48–55.
[PubMed]
93.
Lin YW, Zhou QT, Han ML, Onufrak NJ, Chen K, Wang J, et al. Mechanism-based
pharmacokinetic/pharmacodynamic modeling of aerosolized colistin in a mouse
lung infection model. Antimicrob Agents Chemother. 2018;62(3):e01965-17.
[PubMed][PubMedCentral]
https://t.me/medicina_free
Index
A
Aerosolised vaccine
Antimicrobial peptides and proteins (APPs)
B
Bacteria
Bacteriophages
Biological barriers
Biologics
D
Dry powder inhaler (DPI)
Dry powders
Dysbiosis
E
Epidemics
I
Infection
Inlammation
Inluenza
Inhalation
Inhalation therapy
L
Lung disorders
Lung infections
Lungs
M
Mathematical model
Microbiome
Model-informed drug development (MIDD)
Monoclonal antibody (mAb)
https://t.me/medicina_free
Mucosal immunity
Mucus
Multi-drug resistance
Multidrug-resistant (MDR) bacteria
N
Nanoformulation
Nebuliser
Nucleic acids (NAs)
P
Particle design
Peptides
Phages
Pharmacodynamics (PD)
Pharmacokinetics (PK)
Probiotics
Pulmonary delivery
R
Respiratory infections
RNA therapeutics
S
Spray drying
T
Therapeutic antibody
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана